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First Report of KPC-2-Producing Klebsiella pneumoniae Strains in Brazil
The carbapenems are regarded as the preferential therapeu-
tic option for treatment of serious health care-associated in-
fections with multidrug-resistant gram-negative bacteria. Al-
though carbapenem resistance is rarely described for the
Enterobacteriaceae (6), this phenotype of resistance has been
increasingly reported worldwide, especially due to the emer-
gence and spread of Klebsiella pneumoniae carbapenemase
(KPC) (1, 5, 8). In this report, we describe the first detection of
KPC-2-producing K. pneumoniae strains in Brazil. These
strains also coproduced an extended-spectrum -lactamase,
CTX-M-2.
Between September and November 2006, four carbapenem-
resistant K. pneumoniae strains were isolated from four distinct
patients hospitalized in an intensive care unit (ICU) of a ter-
tiary hospital located in Recife, a city on the northeastern coast
of Brazil. These strains were isolated from blood (two strains)
or urine (two strains). The antimicrobial susceptibility profile
was determined by the reference agar dilution method accord-
ing to CLSI guidelines (2). The genetic relatedness of the
carbapenem-resistant K. pneumoniae strains was evaluated by
pulsed-field gel electrophoresis (PFGE) using SpeI (4). The
presence of blaTEM, blaSHV, blaCTX, blaKPC, blaIMP, blaVIM,
and blaSPM was determined by PCR using specific primers.
Amplicons were sequenced and compared to sequences available
in the GenBank database (http://blast.ncbi.nlm.nih.gov/Blast.cgi).
Plasmid DNA was extracted from carbapenem-resistant K. pneu-
moniae strains using the QIAprep SpinMiniprep kit (Qiagen,
Hilden, Germany). Transformation experiments with Escherichia
coli DH10B were carried out by electroporation. Transformants
were selected on Mu¨eller-Hinton agar containing ampicillin (100
g/ml), ceftazidime (2 g/ml), and ertapenem (0.5 g/ml). The
MICs ofE. coliDH10B and transformants were determined using
Etest strips according to the manufacturer’s recommendations
(AB Biodisk, Solna, Sweden).
All carbapenem-resistant K. pneumoniae clinical strains
showed resistance to broad-spectrum cephalosporins and car-
bapenems (Table 1). Three carbapenem-resistant K. pneu-
moniae strains showed a unique PFGE pattern (pattern A),
which was distinct from PFGE pattern B, displayed only by a
single strain (7). blaKPC and blaCTX-M-2 were detected in all
clinical strains, while blaSHV and blaTEM were carried only by
the PFGE pattern A strains. The carbapenem-resistant
K. pneumoniae clinical isolates and transformants possessed
blaKPC-2 (GenBank accession number EU784136) and blaCTX-M-2,
which were carried by a single 60-kb plasmid. This fact could
justify the increased MICs of several -lactams exhibited by
the transformant (Table 1). Furthermore, as recently de-
scribed, our KPC-producing isolates were found to accumu-
late other -lactam resistance enzymes (TEM-1, CTX-M-2,
and SHV-11) (3).
The report of KPC-2-producing isolates is very worrisome,
since these strains are resistant to all -lactam agents and often
to other antimicrobials. This attribute limits the therapeutic
options available for treatment of serious infections, which is
basically restricted to tigecycline and polymyxins. In addition,
the detection of such strains by routine clinical laboratories
might be difficult when current standard antimicrobial suscep-
tibility methods are employed. Moreover, blaKPC-2 is plasmid
borne, making its dissemination easier, especially when carried
by K. pneumoniae, an organism notorious for its ability to
accumulate and transfer resistance determinants. The clonal
spread observed in this Brazilian ICU confirms blaKPC-2 dis-
semination and points to difficulties with infection control
measures for this organism.
(This report was presented in part at the 47th Annual In-
terscience Conference on Antimicrobial Agents and Chemo-
therapy, Chicago, IL, 2007 [slide session C2-1929].)
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